Activase® (Alteplase) is a tissue plasminogen activator produced by recombinant DNA technology. It is a sterile, purified glycoprotein of 527 amino acids.
Acute Myocardial Infarction
Activase® (Alteplase) is indicated for use in the management of acute myocardial infarction in adults for the improvement of ventricular function following AMI, the reduction of the incidence of congestive heart failure, and the reduction of mortality associated with AMI. Treatment should be initiated as soon as possible after the onset of AMI symptoms (see CLINICAL PHARMACOLOGY).
Acute Ischemic Stroke
Activase® (Alteplase) is indicated for the management of acute ischemic stroke in adults for improving neurological recovery and reducing the incidence of disability. Treatment should only be initiated within 3 hours after the onset of stroke symptoms, and after exclusion of intracranial hemorrhage by a cranial computerized tomography (CT) scan or other diagnostic imaging method sensitive for the presence of hemorrhage (see CONTRAINDICATIONS).
Activase® (Alteplase) is indicated in the management of acute massive pulmonary embolism (PE) in adults:
For the lysis of acute pulmonary emboli, defined as obstruction of blood flow to a lobe or multiple segments of the lungs.
For the lysis of pulmonary emboli accompanied by unstable hemodynamics, e.g., failure to maintain blood pressure without supportive measures.
The diagnosis should be confirmed by objective means, such as pulmonary angiography or noninvasive procedures such as lung scanning.
Published Studies Related to Activase (Alteplase)
Increased benefit of alteplase in patients with ischemic stroke and a high body
(PAIS) trial... CONCLUSION: Patients with ischemic stroke and a high body temperature may have a
The effects of alteplase 3 to 6 hours after stroke in the EPITHET-DEFUSE combined
dataset: post hoc case-control study. 
using coregistration techniques... CONCLUSIONS: The data provide further evidence that alteplase significantly
Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design. [2011.08]
BACKGROUND: TNK-S2B, an innovative, randomized, seamless phase II/III trial of tenecteplase versus rt-PA for acute ischemic stroke, terminated for slow enrollment before regulatory approval of use of phase II patients in phase III. PURPOSE: (1) To review the trial design and comprehensive type I error rate simulations and (2) to discuss issues raised during regulatory review, to facilitate future approval of similar designs... CONCLUSIONS: (1) The design was innovative and efficient. Per protocol, type I error was well controlled for the co-primary phase III hypothesis tests, and experiment-wise. (2a) Time must be allowed for communications with regulatory reviewers from first design stages. (2b) Adequate type I error control must be demonstrated. (2c) Greater clarity is needed on (i) whether this includes demonstration of type I error control if the protocol is violated and (ii) whether simulations of type I error control are acceptable. (2d) Regulatory agency concerns that protocols for futility stopping may not be followed may be allayed by submitting interim analysis results to them as these analyses occur.
SYNTHESIS expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast-track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke. [2011.06]
Rationale Reperfusion in ischemic stroke can be pursued by either systemic intravenous thrombolysis or endovascular treatment. However, systemic intravenous thrombolysis with alteplase within 4.5 h of symptom onset in selected patients is the only medication of proven efficacy... Secondary: neurological deficit seven-days after thrombolysis and the safety of the procedure on the basis of events reported within seven-days following thrombolysis - symptomatic cerebral hemorrhage, fatal and nonfatal stroke, death from any cause, neurological deterioration.
Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in
acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design. 
facilitate future approval of similar designs... CONCLUSIONS: (1) The design was innovative and efficient. Per protocol, type I
Clinical Trials Related to Activase (Alteplase)
IV vs. IA tPA (Activase) in Acute Ischemic Stroke With CTA Evidence of Major Vessel Occlusion [Active, not recruiting]
Stroke is the third leading cause of death in the United States, responsible for 158,488
deaths in 1998 (American Heart Association). Nationwide, each year, an estimated 600,000 to
750,000 people suffer a new or recurrent stroke. Cerebral infarction comprises 80% of all
strokes and is the result of a complex series of cellular metabolic events that occur rapidly
after interruption of blood flow to a region of the brain. The extent of the brain damage is
dependent on the duration and severity of the cerebral ischemia. Acute thrombus formation or
migration is the principal cause of blood flow interruption in at least 75% of cerebral
infarctions. In several animal models of focal cerebral ischemia, restoration of cerebral
blood flow within two to six hours after initial occlusion has been associated with smaller
volumes of cerebral infarction and improved functional outcome. An effective way of
dissolving the thrombus is by administration of recombinant tissue plasminogen activator or
Activase (Alteplase, rt-PA), which promotes the proteolytic action of plasmin from
plasminogen at the site of a clot. In this study, the drug, Activase, will be administered in
subjects with acute ischemic stroke (AIS) intravenously (IV) or by local intra-arterial (IA)
injection. The use of the intravenous administration within 3 hours of stroke symptom onset
is FDA approved whereas the intra-arterial administration, despite evidence of potential
benefit, is not currently FDA approved. Although not FDA approved, this study will evaluate
the effectiveness of IA thrombolysis with Activase, used in AIS because of its higher rate of
recanalization , potential expansion of the time window out to 6 hours, and lower doses of
thrombolytic agent used compared with systemic or intravenous Activase. The study is designed
to test the feasibility and provide preliminary safety data regarding the relative benefits
and risks of IA Activase as compared to IV Activase when administered per the NINDS rt-PA
stroke study protocol, i. e. randomized within 3 hours of onset of symptoms of ischemic stroke
then treated within 3 hours in the IV Activase arm and within 4 hours in the IA Activase
Cathflo Activase Pediatric Study [Completed]
This was a Phase IV, open-label, single-arm, multicenter trial that was to be conducted at
~60 sites in the United States. Approximately 300 pediatric subjects with dysfunctional
CVADs (including catheters with valves, multiple lumens, umbilical catheters, and implanted
ports) were to be treated with up to two serially instilled doses of Cathflo Activase.
Interventional Management of Stroke (IMS) III Trial [Recruiting]
The purpose of this study is to compare two different treatment approaches—combined
intravenous and intra-arterial treatment including recombinant tissue plasminogen activator
(rt-PA) and standard intravenous (IV) rt-PAâto restoring blood flow to the brain.
EffIcicy and Safety of Activase vs Placebo in CPE/Empyemas [Recruiting]
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke [Recruiting]
The primary goal of this trial is to determine if individuals with acute ischemic stroke
treated with a medium dose of IV rt-PA plus IV eptifibatide started within 3 hours of
symptom onset are more likely to have a better outcome than individuals treated with
standard IV rt-PA alone.
Reports of Suspected Activase (Alteplase) Side Effects
Chest Pain (32),
Cerebral Haemorrhage (28),
Brain Oedema (14),
Ventricular Tachycardia (11),
Haemorrhage Intracranial (10), more >>
Page last updated: 2014-11-30